Point-of-Care Opioid Testing Market

Point-of-Care Opioid Testing Market Size and Share Forecast Outlook 2025 to 2035

The Point-of-Care Opioid Testing Market is estimated to be valued at USD 496.2 billion in 2025 and is projected to reach USD 782.0 billion by 2035, registering a compound annual growth rate (CAGR) of 4.7% over the forecast period.

Quick Stats for Point-of-Care Opioid Testing Market

• Point-of-Care Opioid Testing Market Industry Value (2025): USD 496.2 billion
• Point-of-Care Opioid Testing Market Forecast Value (2035): USD 782.0 billion
• Point-of-Care Opioid Testing Market Forecast CAGR: 4.7%
• Leading Segment in Point-of-Care Opioid Testing Market in 2025: Strips (48.6%)
• Key Growth Region in Point-of-Care Opioid Testing Market: North America, Asia-Pacific, Europe
• Top Key Players in Point-of-Care Opioid Testing Market: Avon Healthcare, Triveni Traders & Diagnostic Private Limited, AdvaCare Pharma USA, BTNX Inc., Phamatech, ADC, Worldwide Medical Corporation, Accu-Stat Diagnostics, Inc, ACON Laboratories, Inc., Alere, Innovacon, Inc., Amedica Biotech, Inc, Branan Medical Corporation, Biosite Inc, UCP Biosciences, Inc, TransMed Company, Vitrosens Biotechnology, Abbot, clarity diagnostics, Alcotec Company Limited

Metric	Value
Point-of-Care Opioid Testing Market Estimated Value in (2025 E)	USD 496.2 billion
Point-of-Care Opioid Testing Market Forecast Value in (2035 F)	USD 782.0 billion
Forecast CAGR (2025 to 2035)	4.7%

Rationale for Segmental Growth in the Point of Care Opioid Testing Market

The point of care opioid testing market is witnessing consistent expansion driven by the rising prevalence of opioid misuse, growing focus on rapid diagnosis, and increasing adoption of decentralized testing solutions in both clinical and non clinical environments. The ability to deliver immediate results without the need for advanced laboratory infrastructure has strengthened adoption across emergency care, law enforcement, rehabilitation centers, and workplace testing programs.

Technological advances in lateral flow assays, digital integration, and portable analyzers are enhancing the accuracy and usability of these tests. Regulatory initiatives aimed at curbing the opioid crisis are further promoting adoption through funding and awareness programs.

The market outlook remains positive as demand for fast, reliable, and scalable solutions grows in alignment with public health strategies and regulatory mandates addressing the opioid epidemic.

Segmental Analysis

Insights into the Strips Product Segment

The strips segment is projected to account for 48.60% of total revenue by 2025 within the product category, establishing it as a leading segment. This dominance is supported by their cost effectiveness, ease of use, and rapid result generation.

Strips are particularly suitable for large scale screening initiatives and home based applications, where affordability and accessibility are critical. Their compatibility with multiple biological samples and minimal training requirements has also contributed to their strong market share.

As healthcare providers and community programs seek affordable diagnostic solutions, strips continue to serve as a reliable option for immediate opioid detection.

Insights into the Single Panel Drug Test Kits Modality Segment

The single panel drug test kits segment is expected to contribute 55.20% of total market revenue by 2025, making it the leading modality. This prominence is attributed to their simplicity, accuracy, and ability to provide rapid results for a specific drug of concern.

Their focused approach has been valuable in high risk environments such as emergency response and law enforcement, where immediate decisions are necessary. Cost efficiency and faster processing compared to multi panel kits have supported widespread adoption.

The segment’s growth is further reinforced by their scalability in both clinical and non clinical use cases, cementing their leadership in the modality category.

Insights into the Saliva Sample Segment

The saliva sample segment is projected to account for 42.70% of market revenue by 2025, positioning it as the leading sample type. Saliva based testing has gained preference due to its non invasive nature, ease of collection, and reduced risk of adulteration compared to urine samples.

Its suitability for roadside testing, workplace monitoring, and home based screening has increased demand significantly. Advances in assay sensitivity for saliva samples have also improved reliability, making them a trusted option for opioid detection.

With growing emphasis on user friendly and tamper resistant testing methods, the saliva segment continues to dominate in the point of care opioid testing market.

2020 to 2024 Point-of-Care Opioid Testing Market Demand Outlook Compared to 2025 to 2035 Forecast

From 2020 to 2025, the global point-of-care opioid testing market experienced a CAGR of 3.9%, reaching a market size of USD 496.2 million in 2025.

From 2020 to 2025, the global point-of-care opioid testing industry witnessed significant growth as advancements in testing technologies have significantly contributed to the historic growth of the market.

The development of point-of-care testing with improved accuracy, sensitivity, and speed has facilitated rapid screening and early detection of opioid use. These technological advancements have enhanced the convenience and accessibility of testing, leading to increased adoption and market growth.

Future Forecast for Point-of-Care Opioid Testing Market Industry:

Looking ahead, the global point-of-care opioid testing market industry is expected to rise at a CAGR of 4.9% from 2025 to 2035. During the forecast period, the market size is expected to reach USD 782 million by 2035.

The point-of-care opioid testing industry is expected to continue its growth trajectory from 2025 to 2035, driven by increasing emphasis on patient-centered care and remote monitoring, there will be a growing demand for convenient and accessible testing options that can be performed in the comfort of one's home.

Home-based testing kits and connected devices will empower individuals to monitor their opioid use, promote self-management, and facilitate remote consultations with healthcare providers.

Country-wise Insights in the Point-of-Care Opioid Testing Market

Point-of-Care Opioid Testing Market to Surge in the United States Due to Increased Focus on Addressing the Opioid Crisis

Country	The United States
Market Size (USD million) by End of Forecast Period (2035)	USD 782 million
CAGR % 2025 to End of Forecast (2035)	4.2%

The point-of-care opioid testing industry in the United States is expected to reach a market size of USD 782 million by 2035, expanding at a CAGR of 4.2%. The opioid crisis remains a significant driver of the point-of-care opioid testing market in the United States.

The increasing prevalence of opioid misuse and addiction has prompted healthcare providers, policymakers, and stakeholders to prioritize interventions and strategies to combat the crisis. Point-of-care opioid testing plays a crucial role in identifying opioid use, enabling early intervention, and monitoring treatment progress.

Technological Advancement in United Kingdom Has Propelled the Market

Country	The United Kingdom
Market Size (USD million) by End of Forecast Period (2035)	USD 32.0 million
CAGR % 2025 to End of Forecast (2035)	4.3%

The point-of-care opioid testing industry in the United Kingdom is expected to reach a market value of USD 32.0 million, expanding at a CAGR of 4.3% during the forecast period. Recent advancements in testing technologies have influenced the point-of-care opioid testing market in the UK.

These advancements include the development of more accurate, sensitive, and user-friendly testing devices. Point-of-care opioid testing technologies, such as immunoassays, oral fluid tests, and urine tests, have become more reliable and accessible, supporting wider adoption in various healthcare settings.

Notable Growth Expected in China's Point-of-Care Opioid Testing Market due to Rising Awareness & Education

Country	China
Market Size (USD million) by End of Forecast Period (2035)	USD 54.7 million
CAGR % 2025 to End of Forecast (2035)	6.4%

The point-of-care opioid testing industry in China is anticipated to reach a market size of USD 54.7 million, moving at a CAGR of 6.4% during the forecast period. The Chinese government has implemented initiatives and policies to combat substance abuse and improve public health outcomes.

These initiatives include strengthening regulations on opioid medications, establishing rehabilitation centers, and promoting the use of point-of-care opioid testing in healthcare facilities. Government support and policies have been crucial drivers for the adoption and growth of the point-of-care opioid testing market in China.

Research & Development Efforts in Opioid Test Kits is Driving Market Growth in Japan

Country	Japan
Market Size (USD million) by End of Forecast Period (2035)	USD 39.9 million
CAGR % 2025 to End of Forecast (2035)	6.2%

The point-of-care opioid testing industry in Japan is estimated to reach a market size of USD 39.9 million by 2035, thriving at a CAGR of 6.2%. Japan has seen increased research and development efforts in the field of point-of-care opioid testing. Academic institutions, research organizations, and healthcare companies are investing in the development of innovative testing methodologies, biomarkers, and data analysis algorithms.

This driver fosters continuous innovation, advancements in testing technologies, and the potential for personalized medicine approaches in opioid addiction management.

Demand for Point-of-care opioid testing Market is Rising Due to Stringent Regulations & Monitoring

Country	South Korea
Market Size (USD million) by End of Forecast Period (2035)	USD 45.4 million
CAGR % 2025 to End of Forecast (2035)	6.0%

The point-of-care opioid testing industry in South Korea is expected to reach a market size of USD 45.4 million, expanding at a CAGR of 6.0% during the forecast period. The South Korean government has implemented stricter regulations and monitoring measures for opioid medications.

These regulations aim to prevent misuse, addiction, and illegal distribution of opioids. The increased focus on monitoring drives the adoption of point-of-care opioid testing as a tool to ensure compliance with regulations and enhance patient safety.

Category-wise Insights in the Point-of-Care Opioid Testing Market

Which Product Are Driving the Point-of-care opioid testing Market?

Test strips are expected to dominate the point-of-care opioid testing industry with a CAGR of 4.7% from 2025 to 2035. Test strips are available for different sample types, including urine, saliva, and blood.

Urine is the most commonly used sample type for point-of-care opioid testing due to its ease of collection and high concentration of detectable substances. Saliva and blood samples may also be used in certain situations, such as in clinical laboratory settings or for specific testing requirements.

Which Modality Are Driving the Point-of-care opioid testing Market?

Multi-panel drug test kits are expected to dominate the point-of-care opioid testing industry with a CAGR of 5.2% from 2025 to 2035. Multi-panel kits allow for simultaneous testing of multiple drugs within a single device. Each drug panel on the test kit contains specific reagents or antibodies that react with the targeted drugs or their metabolites. When the sample is applied to the kit, it flows through the different panels, and if any of the targeted drugs are present, corresponding lines or color changes appear on the test result window.

Which Sample Are Driving the Point-of-care opioid testing Market?

Blood sample are expected to dominate the point-of-care opioid testing industry with a CAGR of 4.9% from 2025 to 2035. Blood samples provide a higher level of sensitivity and specificity compared to urine and saliva samples. The concentration of opioids and their metabolites in blood is generally higher and offers a more accurate representation of recent drug use. This makes blood testing particularly valuable in cases where precise quantification and detection of specific opioid compounds are required.

Which End User is Widely Adopted the Point-of-care opioid testing Market?

Forensic Laboratories is expected to dominate the point-of-care opioid testing industry with a CAGR of 5.4% from 2025 to 2035. Forensic laboratories play a crucial role in confirming preliminary point-of-care test results.

Point-of-care tests provide rapid screening but may have limitations in terms of sensitivity and specificity. Forensic laboratories perform confirmatory testing to validate the presence of opioids and determine the precise concentration or level of opioids in a sample. This information is essential for legal proceedings, workplace incidents, and clinical decision-making.

How Key Players Stay Competitive in the Point-of-Care Opioid Testing Industry

The point-of-care opioid testing market is fiercely competitive, with many companies fighting for market dominance. To stay ahead of the competition in such a circumstance, essential players must develop effective conjugates.

Key Strategies Used by the Participants

Product Development

Companies are investing in research & development to deliver product that improve efficiency, dependability, and cost-effectiveness. Product innovation allows businesses to differentiate themselves from their competition while also catering to the changing demands of their clients.

Strategic Alliances & Collaborations

Key industry leaders frequently develop strategic partnerships and collaborations with other companies in order to harness their strengths and increase their market reach. Companies might also gain access to new technology and markets through such agreements.

Expansion into Emerging Markets

The point-of-care opioid testing market is expanding rapidly in emerging regions such as China and India. Key firms are enhancing their distribution networks and developing local manufacturing facilities to increase their presence in these areas.

Acquisitions and mergers

Mergers and acquisitions are frequently used by key players in the point-of-care opioid testing industry to consolidate their market position, extend their product range, and gain access to new markets.

Key Players in the Point-of-Care Opioid Testing Industry

• Avon Healthcare
• Triveni Traders & Diagnostic Private Limited
• AdvaCare Pharma USA
• BTNX Inc.
• Phamatech
• ADC
• Worldwide Medical Corporation
• Accu-Stat Diagnostics, Inc
• ACON Laboratories, Inc.
• Alere
• Innovacon, Inc.
• Amedica Biotech, Inc
• Branan Medical Corporation
• Biosite Inc
• UCP Biosciences, Inc
• TransMed Company
• Vitrosens Biotechnology
• Abbot
• clarity diagnostics
• Alcotec Company Limited

Key Developments in the Point-of-care opioid testing Market:

• In November 2025, Abbott receives three CES 2025 Innovation awards for advancements in health technology.
• In August 2020, Intoximeters and Abbott recently established a partnership to commercialise Abbott's SoToxaTM Mobile Test System, a portable oral fluid roadside testing device that accurately and quickly identifies recent drug use.

Segmentation Analysis of the Point-of-Care Opioid Testing Market

By Product:

• Strips
• Cassettes
• Drug Test Dip Cards

By Modality:

• Single-panel Drug Test Kits
• Multi-panel Drug Test Kits

By Sample:

• Saliva
• Blood
• Urine
• Others

By End User:

• Hospitals
• Diagnostics Laboratories
• Forensic Laboratories
• Home Care Settings
• Others

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• The Middle East & Africa